To analyze the humoral and cellular immunization in patients with Multiple Sclerosis treated with different DMTs after SARS CoV-2 vaccination
Latest Information Update: 06 Apr 2022
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 06 Apr 2022 New trial record
- 26 Feb 2022 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022